Patents by Inventor Alonzo H. Ross

Alonzo H. Ross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING GLIOBLASTOMA
    Publication number: 20140187495
    Abstract: Described are methods for treating cancers, e.g., glioblastoma, including administering an inhibitor of Notch signalling, e.g., a gamma secretase inhibitor, in combination with a chemotherapeutic agent.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 3, 2014
    Applicant: University of Massachusetts
    Inventors: Alonzo H. Ross, Candace Gilbert, Richard Moser
  • Methods for treating glioblastoma
    Patent number: 8637493
    Abstract: Described are methods for treating cancers, e.g., glioblastoma, including administering an inhibitor of Notch signalling, e.g., a gamma secretase inhibitor, in combination with a chemotherapeutic agent.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: January 28, 2014
    Assignee: University of Massachusetts
    Inventors: Alonzo H. Ross, Candace Gilbert, Richard Moser
  • Methods for Treating Glioblastoma
    Publication number: 20110178046
    Abstract: Described are methods for treating cancers, e.g., glioblastoma, including administering an inhibitor of Notch signalling, e.g., a gamma secretase inhibitor, in combination with a chemotherapeutic agent.
    Type: Application
    Filed: November 10, 2010
    Publication date: July 21, 2011
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Alonzo H. Ross, Candace Gilbert, Richard Moser
  • Cancer treatment by expression of differentiation factor receptor
    Patent number: 6271205
    Abstract: Disclosed are methods of reducing or inhibiting the motility and/or proliferative abilities of a neural tumor cell, or of enhancing apoptosis or differentiation of the tumor cell, in which a vector comprising a nucleic acid encoding a cytoplasmic domain of a neurotrophin receptor tyrosine kinase, is transferred to the tumor cell such that the nucleic acid is expressed. The methods of the invention result in reduced tumorigenicity of neural tumors.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: August 7, 2001
    Assignees: University of Massachusetts Medical Center, Worcester Foundation for Biomedical Research
    Inventors: Alonzo H. Ross, Lawrence D. Recht, Mahesh B. Lachyankar
  • Identification of differentiation factor receptors which inhibit the tumorigenicity of neuroblastoma cells in a ligand-independent manner
    Patent number: 5789187
    Abstract: Disclosed is a method of reducing or inhibiting the tumorigenicity of a tumor cell in which a vector including a nucleotide sequence encoding a differentiation factor receptor, or a polypeptide portion thereof, is transferred to the tumor cell such that the nucleotide sequence is expressed. Tumorigenicity is monitored by cell growth and colony formation in a semi-soft medium, a reduction in proliferation being indicative of the reduction or inhibition of tumorigenicity of the treated tumor cell.
    Type: Grant
    Filed: September 21, 1994
    Date of Patent: August 4, 1998
    Assignee: Worcester Foundation for Experimental Biology
    Inventors: Alonzo H. Ross, Wojciech Poluha, Mahesh B. Lachyankar, Dorota K. Poluha
  • Treatment of tumor cells in vitro with neurotrophic factors and cell proliferation inhibitors
    Patent number: 5387520
    Abstract: Disclosed are methods and compositions for treating neuroblastoma cells. The methods include contacting the neuroblastoma cells with a neurotrophic factor and less than a lethal dose of an inhibitor of cell proliferation for about 1 to 15 days, and then maintaining the neuroblastoma cells in contact with the neurotrophic factor for an additional 1 to 15 days. The composition includes a neurotrophic factor such as the neurotropin, nerve growth factor, and an inhibitor of cell proliferation such as aphidicolin, thymidine, or hydroxyurea. Also disclosed are methods for inducing the remission or differentiation of, or eliminating, neuroblastoma cells.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: February 7, 1995
    Assignee: Worcester Foundation for Experimental Biology
    Inventors: Patrizia LoPresti, Wojciech Poluha, Dorota K. Poluha, Alonzo H. Ross
  • Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
    Patent number: 4543439
    Abstract: A hybridoma cell line is disclosed that secretes monoclonal antibodies which serve as a high titer, reproducible, biological reagent useful in biological/medical research for isolating and identifying phosphotyrosine-containing proteins. In addition, the antibodies have potential uses in diagnosis of a variety of diseases, including certain cancers. The antibodies, which have demonstrated affinity for a variety of molecules containing o-phosphotyrosine residues, were prepared using a synthetic analog, p-azobenzyl phosphonate (ABP) covalently linked to a carrier protein, as the antigen.
    Type: Grant
    Filed: December 13, 1982
    Date of Patent: September 24, 1985
    Assignee: Massachusetts Institute of Technology
    Inventors: A. Raymond Frackelton, Jr., Herman N. Eisen, Alonzo H. Ross